Head-To-Head Survey: Affymax (AFFY) vs. Athersys (ATHX)

Athersys (NASDAQ:ATHX) and Affymax (OTCMKTS:AFFY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Earnings & Valuation

This table compares Athersys and Affymax’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athersys $3.71 million 70.97 -$32.24 million ($0.29) -6.55
Affymax N/A N/A N/A N/A N/A

Affymax has lower revenue, but higher earnings than Athersys.

Analyst Recommendations

This is a breakdown of current recommendations for Athersys and Affymax, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athersys 0 0 1 0 3.00
Affymax 0 0 0 0 N/A

Athersys presently has a consensus price target of $6.00, suggesting a potential upside of 215.79%. Given Athersys’ higher probable upside, research analysts plainly believe Athersys is more favorable than Affymax.

Risk & Volatility

Athersys has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500. Comparatively, Affymax has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500.


This table compares Athersys and Affymax’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Athersys -106.99% -61.52% -47.17%
Affymax N/A N/A N/A

Insider and Institutional Ownership

18.9% of Athersys shares are owned by institutional investors. 18.6% of Athersys shares are owned by insiders. Comparatively, 1.6% of Affymax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Athersys beats Affymax on 5 of the 9 factors compared between the two stocks.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

About Affymax

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply